All:
Most if not all of SENS is based on applications of known technology.
What about that thing with the mitochondria?
See (1,2) for proof-of-concept of allotopic expression in rat models
in vivo ((1) is Methuselah Foundation-funded work, BTW). See (3) for another, less-advanced strategy
in vivo, and (4) for a yet-less-advanced (and, to be frank,
prima facie, somewhat difficult to swallow) approach.
if i can rephrase with greater specificity: 1. what is the known technology that can enable the mitochondrial genes to be relocated in the nucleus per se.
(1,2) above; also cell models not exploiting the mRNA localization trick, and other tricks proposed to facilitate AE (inteins, protein evolution to reduce hydrophobicity), but only in cell models or conceptual. However, if AE
per se doesn't work, that's fine: if Adhya's method can be done (and more clearly demonstrated) for larger mRNAs, or any other method of obviating mtDNA deletions looks more promising than AE, the Foundation will fund that route instead. We're looking for operational outcomes, not wedded to specific biotechnologies.
2. then for this to be done in an adult organism.
I would be cheating, of course, to point back to (1), since we certainly won't use electroporation. But the answer is reasonably obvious: somatic gene therapy, which is already reasonably easy in mice and beginning to show fruits in humans (the recent progress in using gene therapy in
children with Leber congenital amaurosis type 2,
postmenopausal women with advanced rheumatoid arthritis). I take it that you would agree that nuclear gene therapy in humans is itself foreseeable biotech ...?
3. and finally to make sure the transplanted gene regulation isnt altered?
You have to remember that the majority of the OXPHOS machinery is already nu-encoded; we can either actively make use of the same machinery for regulation of expression (since there are nu-encoded OXPHOS proteins in the same Complex as (and thus requiring fixed stoichiometry with) mt-encoded ones), or rely on existing mechanisms whereby mt control the level or activity of nu-coded proteins (regulating their importation rate or modulating enzyme activity allosterically, eg (5)). Some of the main arguments about the
regulation of allotopically-expressed mitochondrial proteins were discussed a while ago on these Forums.
Elrond, why is there a replenisens section if sens does not actually have a research program/strategy in this area?
Because they're part of SENS:
cell loss and tissue atrophy is one of the seven classes of aging damage that we need to repair to arrest aging, and
RepleniSENS (cell therapy and tissue engineering) is the 'engineering' solution. As Elrond indicates,
At no point does aubrey or anyone make the claim that the MF will be doing all of it. You realize he came up with it before there was such a thing as an MF?
The Foundation is using a critical-path analysis to target its research dollars to the areas under least vigorous pursuit by existing funding bodies. RepleniSENS is presently receiving a great deal of vigorous research, and thus is a low priority. (Similarly, not a dime of Foundation money is going into immunotherapy for beta-amyloid protein -- though there is an RFP out for another subclass of
AmyloSENS (immunotherapy for TTR), because no one is working on that yet (except indirectly, through a possible cross-reactivity with an Ab targeting light-chain amyloid (6,7)).
my point is, why is there such a thing as replenisens if there is no project behind it? particularly given there's a 'donate' button on the same page.. its confusing. i mean say someone obtains the view they are donating to replenisens?
You wouldn't get this confusion by clicking through into or out of this page, or on the 'Donate' button; in any case, the button is on every page of the website, as with the equivalent link on every page of other medical research charities like the American Heart Association, American Diabetes Association, or American Cancer Society, irrespective of whether the organization is funding the work described on a given page.
-Michael
References
1. Ellouze S, Augustin S, Bouaita A, Bonnet C, Simonutti M, Forster V, Picaud S, Sahel JA, Corral-Debrinski M.
Optimized allotopic expression of the human mitochondrial ND4 prevents blindness in a rat model of mitochondrial dysfunction.
Am J Hum Genet. 2008 Sep;83(3):373-87. Epub 2008 Sep 4.
PMID: 18771762 [PubMed - indexed for MEDLINE]
2. Qi X, Sun L, Lewin AS, Hauswirth WW, Guy J.
The mutant human ND4 subunit of complex I induces optic neuropathy in the mouse.
Invest Ophthalmol Vis Sci. 2007 Jan;48(1):1-10.
PMID: 17197509 [PubMed - indexed for MEDLINE]
3. Mukherjee S, Mahata B, Mahato B, Adhya S.
Targeted mRNA degradation by complex-mediated delivery of antisense RNAs to intracellular human mitochondria.
Hum Mol Genet. 2008 May 1;17(9):1292-8. Epub 2008 Jan 18.
PMID: 18203752 [PubMed - indexed for MEDLINE]
4. Development of mitochondrial gene replacement therapy.
Khan SM, Bennett JP Jr.
J Bioenerg Biomembr. 2004 Aug;36(4):387-93. Review.
PMID: 15377877 [PubMed - indexed for MEDLINE]
5. Bender E, Kadenbach B.
The allosteric ATP-inhibition of cytochrome c oxidase activity is reversibly switched on by cAMP-dependent phosphorylation.
FEBS Lett. 2000 Jan 21;466(1):130-4.
PMID: 10648827 [PubMed - indexed for MEDLINE]
6. Solomon A, Weiss DT, Wall JS.
Therapeutic potential of chimeric amyloid-reactive monoclonal antibody 11-1F4.
Clin Cancer Res. 2003 Sep 1;9(10 Pt 2):3831S-8S.
PMID: 14506180 [PubMed - indexed for MEDLINE]
7. Wall J, Schell M, Hrncic R, Macy S, Wooliver C, Wolfenbarger D, Murphy C, Donnell R, Weiss DT, Solomon A.
Treatment of amyloidosis using an anti-fibril monoclonal antibody: Preclinical efficacy in a murine model of AA-amyloidosis.
In: Bély M, Apáthy A (eds). Amyloid and Amyloidosis. The Proceedings of the IX International Symposium on Amyloidosis. 2001; Budapest, Hungary; David Apathy, 158-60.